BiotechTube

Zoledronic acid + Letrozole

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bone Loss

Conditions

Bone Loss, Breast Cancer

Trial Timeline

May 1, 2003 → Feb 1, 2010

NCT ID
NCT00171340

About Zoledronic acid + Letrozole

Zoledronic acid + Letrozole is a phase 3 stage product being developed by Novartis for Bone Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT00171340. Target conditions include Bone Loss, Breast Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT00171314Phase 3Completed
NCT00171340Phase 3Completed
NCT00050011Phase 3Completed

Competing Products

20 competing products in Bone Loss

See all competitors
ProductCompanyStageHype Score
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
TacrolimusAstellas PharmaPhase 2
52
TacrolimusAstellas PharmaPhase 2
52
MerestinibEli LillyPhase 1
33
FORTEO + PlaceboEli LillyPhase 1
33
Arzoxifene + PlaceboEli LillyPhase 3
77
TanezumabEli LillyPhase 3
77
Anastrozole + TamoxifenAstraZenecaPhase 3
77
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3
77
Zoledronic acidNovartisPhase 3
77
Zoledronic acidNovartisPhase 3
77
NilotinibNovartisPhase 1
33
Reclast (ZOL446, zoledronic acid)NovartisApproved
85
Zoledronic acidNovartisPhase 3
77
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic AcidNovartisPhase 3
77
zoledronic acidNovartisPhase 1
33
Ruxolitinib continuous therapyNovartisPhase 2
52
zoledronic acidNovartisApproved
85

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85